Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher’s Filtration and Separation business, is part of the Life Sciences Solutions segment.

Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of hemorrhagic and thrombotic diseases, detection, and efficacy of thrombolytic and anticoagulant therapy.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

SmartLabs and Sonrai Analytics (Sonrai) today announced a global strategic partnership designed to bring Sonrai's next-generation AI capabilities directly into SmartLabs' network of advanced research centers. Under this agreement, SmartLabs will begin offering Sonrai's AI advanced analytics platform, Sonrai Discovery, to its member companies. Both companies will also develop new laboratory informatics and bespoke AI applications that will integrate experimental and infrastructure data to predict scientific outcomes and accelerate discovery, exclusively to the SmartLabs' network.

MGI Tech has reported that its revenues for the first half of 2025 dropped 8 percent year over year, mainly due to declining instrument sales.

AliveDx said Tuesday that it has registered its multiplex immunoassay analyzer for autoimmune disease and allergy testing with the US Food and Drug Administration as a Class II device that is exempt from premarket authorization requirements.

SD Biosensor, Inc. (KQ137310), a global leader in in-vitro diagnostics from South Korea, announced that its latent tuberculosis (TB) diagnostic product, STANDARD E TB-Feron ELISA (hereafter STANDARD TB-Feron), has been officially included in the World Health Organization (WHO) recommendation list for TB diagnostics. With this milestone, SD Biosensor strengthens its position in the Interferon-Gamma Release Assay (IGRA) market, marking a shift in the competitive landscape and positioning the company alongside leading global players.